众生药业：公司RAY1225注射液是具有全球自主知识产权的创新结构多肽药物

Core Viewpoint - The company Zhongsheng Pharmaceutical (002317) is advancing its innovative drug RAY1225, which has global intellectual property rights and dual agonistic activity for GLP-1 and GIP receptors, showing potential for bi-weekly administration in treating type 2 diabetes and obesity [1] Group 1: Product Development - RAY1225 is an innovative structural polypeptide drug with excellent pharmacokinetic properties [1] - The drug is currently in Phase III clinical trials for the treatment of type 2 diabetes and overweight/obesity patients [1] - RAY1225 has received approval from the U.S. Food and Drug Administration (FDA) to conduct Phase II clinical trials directly in the U.S. for indications related to overweight or obesity [1]